Peptech patent approved
Tuesday, 15 July, 2003
Peptech's application for a patent on antibodies or antibody fragments that bind to a specific tumour necrosis factor (TNF) has been given the green light by US patent authorities.
Managing director Mr Stephen Kwik noted that the new patent enhanced the company's already considerable anti-TNF patent portfolio, and offered the potential for further coverage under the current description.
"As the peptide represents a portion of the TNF molecule, anti-TNF antibodies that bind the peptide could fall under the scope of the patent," Kwik said.
Peptech has already licensed its technology in the fields of antibody therapeutics for inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...
